A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3–4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with serum C-telopeptide (CTx) levels ≤600 ng/L af...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Addison, Christina L., Bouganim, Nathaniel, Hilton, John, Vandermeer, Lisa, Dent, Susan, Amir, Eitan, Hopkins, Sean, Kuchuk, Iryna, Segal, Roanne, Song, Xinni, Gertler, Stan, Mazzarello, Sasha, Dranitsaris, George, Ooi, Daylily, Pond, Gregory, Clemons, Mark
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Clinical Trial
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3962742/
https://ncbi.nlm.nih.gov/pubmed/24638849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-2906-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars